Heart Failure Clinical Trial
ANTHEM-HFrEF Pivotal Study
A multi-center randomized controlled clinical trial to evaluate Autonomic Regulation Therapy with the VITARIA system in patients with symptomatic heart failure and reduced ejection fraction.
ANTHEM-HFrEF is a multi-center, open-label, randomized controlled clinical trial with an adaptive design. Patients with symptomatic heart failure and reduced LVEF will be enrolled and randomized 2:1 to receive VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy (therapy), or to continue receiving stable guideline-directed medical therapy alone (control arm).
Subjects in the therapy arm will receive continuous, periodic VNS stimulation after surgery is completed, and will undergo visits for VNS up titration over a period of 3 months. Subjects in the control arm will also undergo scheduled visits at a similar frequency as the titration visits that are scheduled for subjects in the therapy arm. Data for safety and efficacy assessments will be collected for both study arms at 4 weeks post-randomization, every 3 months for the first 12 months, and every 4 months thereafter.
Age 18 or above
Willing and capable of providing informed consent
Capable of participating in all testing associated with this clinical investigation
Stable, guideline-directed medical therapy for at least 4 weeks before subject screening. Unrestricted changes in diuretics are allowed during the 4 weeks, as long as the subject remains on a diuretic. If the use of an ARNI is being contemplated for a study subject, ARNI should be administered, and GDMT optimized, before the subject is randomized. No more than a 100% increase or 50% decrease of the dosage of any medication other than a diuretic is permitted. For these medications, medication changes within a class are allowed, as long as the equivalent dosage is within these specified limits
Stable symptomatic heart failure NYHA class III; or NYHA class II with a heart failure hospitalization in the previous 12 months. HF hospitalization may include an overnight hospital or hospital-based observation unit stay with a primary diagnosis of HF, or an emergency department visit with a primary diagnosis of HF, and will in either case include documentation of intravenous HF therapy administration or other intervention for HF
Left ventricular ejection fraction (EF) â‰¤ 35% and left ventricular end-diastolic diameter (LVEDD) < 8.0 cm, as confirmed by the core echocardiography laboratory during screening
N-terminal pro-BNP (NT-proBNP) level of at least 800 pg/mL, as determined by the core laboratory; or NT-proBNP level of at least 1200 pg/mL, as determined by the core laboratory, for patients with permanent atrial fibrillation or reporting signs or symptoms of atrial fibrillation at the time that the NT-proBNP sample is drawn
Received a standard cardiac assessment, including history, physical exam, and electrocardiogram, and determined by a heart failure cardiologist and study surgeon to be an appropriate candidate for the study's surgical procedure
Physically capable and willing to perform repeated 6-minute walk tests associated with the study, and having a baseline distance of between 150 and 450 meters. Symptoms limiting the duration of the 6 minute walk test must be due primarily to heart failure
Refractory symptomatic hypotension (systolic blood pressure below 80 mmHg)
Complete AV block treated with unipolar pacemaker therapy
Currently implanted vagus nerve stimulation (VNS) device, baroreceptor activation therapy (BAT) device, other nerve stimulator, artificial or donor heart, or ventricular assist device (VAD)
Heart failure of non-ischemic origin for less than 6 months, or due to congenital heart disease, hypertrophic obstructive cardiomyopathy, or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis)
Moderate (3+) or severe (4+) aortic valve or mitral valve stenosis; moderate (3+) or severe (4+) aortic valve insufficiency; or severe (4+) mitral valve insufficiency
Symptomatic uncontrolled bradycardia
On renal dialysis
Involvement in any concurrent clinical study with an investigational therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 22 Locations for this study
Birmingham Alabama, 35294, United States
Tucson Arizona, 85724, United States
Little Rock Arkansas, 72205, United States
Long Beach California, 90806, United States
Los Angeles California, 90073, United States
Hartford Connecticut, 06102, United States
Jacksonville Florida, 32256, United States
Peoria Illinois, 61606, United States
Muncie Indiana, 47303, United States
Boston Massachusetts, 02111, United States
Burlington Massachusetts, 01805, United States
Ypsilanti Michigan, 48197, United States
Jackson Mississippi, 39216, United States
New York New York, 10025, United States
Cleveland Ohio, 44109, United States
Toledo Ohio, 43606, United States
Hershey Pennsylvania, 17033, United States
Wormleysburg Pennsylvania, 17043, United States
Houston Texas, 77030, United States
Tyler Texas, 75701, United States
Spokane Washington, 99204, United States
Madison Wisconsin, 53792, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.